Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein B, Z, Ra, Rb, Rc, R1, L, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Abstract: An optical image stabilization apparatus includes a first lens, a first reflector, a position sensor, a control component, and a housing configured to enclose the first lens and the first reflector, where the position sensor is connected to the control component. An optical signal is transmitted to the first reflector after passing through the first lens. The first reflector reflects the received optical signal, and the reflected optical signal is projected onto an imaging plane. The position sensor is configured to detect shaking information of the first lens and send the shaking information to the control component. The control component is configured to control, based on the shaking information, the first reflector to rotate by using a first preset direction as an axis, where the first preset direction is a direction that is not parallel to a normal direction of the first reflector.

Abstract: This application discloses an optical module, including a light passing hole, an optical splitter, an optical imaging apparatus, and an optical apparatus, where light entering from the light passing hole is incident on the optical splitter; the optical splitter is configured to split the incident light into two parts, one part of the light enters the optical imaging apparatus, and the other part of the light enters the optical apparatus; the optical imaging apparatus is configured to collect a first image; and the optical apparatus is configured to collect a second image, or the optical apparatus is configured to implement an optical detection function.

Abstract: An automatic focus apparatus for a camera module includes a voice coil motor and a driving unit. The voice coil motor includes a frame, a moving member with a lens, and a magnetic member. The magnetic member is positioned at a side wall of the moving member, the driving unit is positioned at a side plate of the frame. A magnetic field is generated by the driving unit and the magnetic member, the magnetic field drives the moving member with the lens to move, to achieve automatic focus.

Abstract: A compound of Formula (I) is provided: where the variables are defined herein.

Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, isotopic form or stereoisomer thereof, wherein A is a five-membered heteroaryl comprising 1 or 2 non-adjacent heteroatoms, inclusive of X and Y; W, X, Y, Z, L, L1, E, R1, R2b R2c and the dotted circle are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and compounds for use in methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided. Preferred compounds are e.g. 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and related compounds such as e.g. the corresponding derivatives with e.g. a benzoimidazole, indole, benzooxazole, imidazopyridine or imidazole core structure, substituted on ring A by e.g.

Abstract: The present invention provides a crystal form of a 1,2,3-triazolo[1,5-a]pyrazines derivative and a preparation method for the crystal form. Specifically, the present invention provides a crystal form of a compound (S)-N5-(3,4-difluorophenyl)-6-methyl-N3-((R)-1,1,1-trifluoropropan-2-yl)-6,7-dihydro-[1,2,3]triazolo[1,5-c]pyrazine-3,5(4H)-dimethylformamide and a preparation method for the crystal form. The prepared crystal form has good stability and clinical application value.

Abstract: An LED light bulb includes a lamp housing, an LED filament in the lamp housing and a power module. The LED filament includes a first and a second LED sections, a conductive section, a first and a second conductive electrodes and a light conversion layer. Each LED section includes LED chips connected in serial to from a LED string. The conductive section connects one end of the LED string of the first LED section with one end of the LED string of the second sections. The polarities of the ends of the LED strings are the same. The other ends of the LED strings are respectively connected to the first and the second conductive electrodes. The light conversion layer is coated on at least two sides of the LED chips. The power module's terminals are connected to the conductive section and the conductive electrodes.

Abstract: An LED light bulb comprising a lamp housing, a bulb base, connected to the lamp housing, a stem connected to the bulb base and located in the lamp housing; an LED filament, disposed in the lamp housing, where points of the LED filament in an xyz coordinates are defined as x, y, and z, an x-y plane of the xyz coordinates is perpendicular to the height direction of the LED light bulb, an z-axis of xyz coordinates is parallel with the stem, and the projection of the LED filament on the x-y plane, y-z plane and x-z plane respectively has a length L1, L2 and L3, and the length L1, the length L2, and the length L3 are substantially in a ratio of 1:(0.5 to 1):(0.6 to 0.9).

Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, isotopic form, stereoisomer or prodrug thereof, wherein A, B, X, R1, R2a, R2b, R2c, L, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Abstract: An LED light bulb comprising a lamp housing, a bulb base, connected to the lamp housing, a spectral distribution of the light bulb is generally between a wavelength range of about 400 nm to 800 nm, and three peak wavelengths P1, P2, and P3 appear in wavelength ranges corresponding to light emitted by the light bulb, wherein a wavelength of the peak P1 is between 430 nm and 480 nm, a wavelength of the peak P2 is between 480 nm and 530 nm, a wavelength of the peak P3 is between 630 nm and 680 nm.

Abstract: A method may include providing a substrate, where the substrate includes a first main surface and a second main surface, opposite the first main surface. The second main surface may include a stress compensation layer. The method may include directing ions to the stress compensation layer in an ion implant procedure. The ion implant procedure may include exposing a first region of the stress compensation layer to a first implant process, wherein a second region of the stress compensation layer is not exposed to the first implant process.

Abstract: An NFC QR code label according to the present invention comprises: a rectenna for receiving a radio frequency signal from a terminal device and converting the signal into DC power; a ring oscillator activated by receiving the DC power supplied from the rectenna, and producing an oscillation signal having a predetermined frequency; and a light-em QR code flickering in response to the oscillation signal. The light-emitting QR code includes a QR code pattern formed by means of gravure printing using a nonconductor ink.

Abstract: An high-efficiency light bulb, comprising: a lamp housing with inner surface and outer surface opposite to the inner surface of the lamp housing, the lamp housing includes a layer of luminescent material, which is formed on the inner surface or the outer surface of the lamp housing or integrated in the material of the lamp housing; a bulb base connected to the lamp housing; a stem connected to the bulb base and located in the lamp housing; and a single filament, disposed in the light housing, further comprising a plurality of supporting arms, connected with and supporting the LED filament, wherein the stem comprises a stand extending to the center of the lamp housing, the stand supports the supporting arms.

Abstract: The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and/or TCR function through improvement of the tumor microenvironment via improvement in cytokine signaling.

Abstract: An LED filament comprising a plurality of LED filament units, each of the plurality of LED filament units includes a LED chip with an upper surface and a lower surface opposite to the upper surface of the LED chip, and a light conversion layer comprising a top layer and a base layer, and the base layer comprises an upper surface and a lower surface opposite to the upper surface of the base layer, where the top layer with an upper surface and a lower surface opposite to the upper surface of the top layer is disposed on at least two sides of each of the LED chips, the lower surface of each of the LED chips is close to the upper surface of the base layer, and the upper surface of the top layer is away from each of the LED chips.

Abstract: An automatic focus apparatus for a camera module includes a voice coil motor and a driving unit. The voice coil motor includes a frame, a moving member with a lens, and a magnetic member. The magnetic member is positioned at a side wall of the moving member, the driving unit is positioned at a side plate of the frame. A magnetic field is generated by the driving unit and the magnetic member, the magnetic field drives the moving member with the lens to move, to achieve automatic focus.

Abstract: The present invention relates to crystal forms of an oxypyridine amide derivative and a preparation method therefor. In particular, the present invention relates to crystal forms A, B, C, D, E and F of a compound represented by formula (I) and a preparation method therefor. The crystal forms of the compound represented by formula (I) as described in the present invention have good crystal form stability and may be better for clinical use.

Abstract: A method may include providing a substrate, where the substrate includes a first main surface and a second main surface, opposite the first main surface. The second main surface may include a stress compensation layer. The method may include directing ions to the stress compensation layer in an ion implant procedure. The ion implant procedure may include exposing a first region of the stress compensation layer to a first implant process, wherein a second region of the stress compensation layer is not exposed to the first implant process.

Abstract: The present invention provides e.g. 2-(2-acryloyl-2, 6-diazaspiro[3.4]octan-6-yl)-6-(1H-indazol-4-yl)-benzonitrile and e.g. 2-(2-acryloyl-2,7-diazaspiro[3.5]nonan-7-yl)-6-(1H-indazol-4-yl)-benzonitrile derivatives and related compounds of formula (I) as inhibitors of G12C mutant KRAS protein for treating tumor metastasis. The present description discloses exemplary compounds (e.g. pages 53 to 90; table 1; compounds I-1 to I-141), pharmacological data (e.g. page 125 to 128; table 2; example 1) and synthesis thereof (e.g. pages 129 to 143; examples 2 to 7). Exemplary compounds are e.g. 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(5-methyl-1H-indazol-4-yl)-4-morpholinobenzonitrile (example 2; compound I-1) and 6-(2-acryloyl-2,7-diazaspiro[3.5]nonan-7-yl)-3-methoxy-2-(5-methyl-1H-indazol-4-yl)-4-morpholinobenzonitrile (example 7; compound I-84).